Incyte Corp. buy marge
Start price
17.11.16
/
50%
€95.52
Target price
18.09.17
€135.30
Performance (%)
12.51%
End price
18.09.17
€107.47
Summary
This prediction ended on 18.09.17 with a price of €107.47. The prediction had a final performance of 12.51%. marge has a follow-up prediction for Incyte Corp. where he still thinks Incyte Corp. is a Buy. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 6.051% | 6.051% | 29.535% | 25.054% |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% | 68.627% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% | 116.238% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% | 56.217% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% | 70.924% |
Comments by marge for this prediction
In the thread Incyte Corp. diskutieren
marge stimmt der Buy-Einschätzung von datca zu: siehe Beschreibung
marge stimmt am 17.11.2016 der Buy-Einschätzung von datca mit dem Kursziel 120$ zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)